| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Antipsychotic Agents | 48 | 2020 | 887 | 9.61 | Why? |
| Tardive Dyskinesia | 12 | 2018 | 26 | 6.77 | Why? |
| Schizophrenia | 31 | 2020 | 1018 | 6.51 | Why? |
| Psychotic Disorders | 19 | 2019 | 924 | 3.60 | Why? |
| Tetrabenazine | 7 | 2018 | 19 | 3.40 | Why? |
| Aripiprazole | 8 | 2019 | 60 | 2.99 | Why? |
| Valine | 6 | 2018 | 359 | 2.76 | Why? |
| Vesicular Monoamine Transport Proteins | 5 | 2018 | 8 | 2.02 | Why? |
| Psychotropic Drugs | 7 | 2020 | 396 | 1.89 | Why? |
| Clozapine | 7 | 2020 | 218 | 1.83 | Why? |
| Delayed-Action Preparations | 9 | 2019 | 291 | 1.76 | Why? |
| Bipolar Disorder | 6 | 2019 | 744 | 1.71 | Why? |
| Adrenergic Uptake Inhibitors | 3 | 2018 | 11 | 1.68 | Why? |
| Schizophrenic Psychology | 4 | 2019 | 198 | 1.38 | Why? |
| Quetiapine Fumarate | 4 | 2019 | 30 | 1.28 | Why? |
| Prodromal Symptoms | 3 | 2019 | 133 | 1.03 | Why? |
| Psychiatric Status Rating Scales | 9 | 2019 | 1340 | 0.99 | Why? |
| Mood Disorders | 2 | 2017 | 431 | 0.99 | Why? |
| Medication Adherence | 4 | 2019 | 1270 | 0.94 | Why? |
| Benzodiazepines | 3 | 2017 | 163 | 0.88 | Why? |
| Early Medical Intervention | 3 | 2018 | 487 | 0.81 | Why? |
| Sex Hormone-Binding Globulin | 1 | 2019 | 57 | 0.81 | Why? |
| Minocycline | 2 | 2019 | 101 | 0.80 | Why? |
| Long Term Adverse Effects | 2 | 2018 | 119 | 0.79 | Why? |
| Methylphenidate | 1 | 2019 | 36 | 0.79 | Why? |
| Transdermal Patch | 1 | 2019 | 52 | 0.79 | Why? |
| Anti-Mullerian Hormone | 1 | 2019 | 35 | 0.78 | Why? |
| Thiophenes | 1 | 2019 | 78 | 0.77 | Why? |
| Attention Deficit and Disruptive Behavior Disorders | 1 | 2017 | 29 | 0.71 | Why? |
| Restless Legs Syndrome | 1 | 2018 | 53 | 0.70 | Why? |
| Dyskinesias | 1 | 2017 | 13 | 0.70 | Why? |
| Mental Disorders | 10 | 2020 | 6742 | 0.70 | Why? |
| Quinolones | 1 | 2019 | 167 | 0.70 | Why? |
| Double-Blind Method | 14 | 2019 | 5988 | 0.70 | Why? |
| Conduct Disorder | 1 | 2017 | 39 | 0.69 | Why? |
| Education, Nonprofessional | 1 | 2017 | 31 | 0.69 | Why? |
| Antipyretics | 1 | 2018 | 107 | 0.68 | Why? |
| Estradiol | 1 | 2019 | 250 | 0.68 | Why? |
| Delayed Diagnosis | 2 | 2017 | 1529 | 0.65 | Why? |
| Educational Technology | 1 | 2017 | 101 | 0.65 | Why? |
| Attention Deficit Disorder with Hyperactivity | 3 | 2019 | 441 | 0.64 | Why? |
| Electroconvulsive Therapy | 2 | 2018 | 326 | 0.61 | Why? |
| Problem Behavior | 1 | 2017 | 176 | 0.59 | Why? |
| Serum Albumin | 1 | 2019 | 571 | 0.59 | Why? |
| Antidepressive Agents | 5 | 2018 | 509 | 0.59 | Why? |
| Psychomotor Agitation | 1 | 2017 | 208 | 0.58 | Why? |
| Psychometrics | 3 | 2019 | 1269 | 0.52 | Why? |
| Testosterone | 1 | 2019 | 596 | 0.52 | Why? |
| Administration, Oral | 3 | 2019 | 2340 | 0.48 | Why? |
| Parenting | 1 | 2017 | 486 | 0.45 | Why? |
| Neuropsychological Tests | 1 | 2017 | 954 | 0.44 | Why? |
| Social Behavior | 1 | 2019 | 882 | 0.41 | Why? |
| Education | 4 | 2019 | 434 | 0.41 | Why? |
| Meta-Analysis as Topic | 1 | 2017 | 1289 | 0.41 | Why? |
| Randomized Controlled Trials as Topic | 7 | 2020 | 10649 | 0.39 | Why? |
| Liraglutide | 3 | 2018 | 47 | 0.39 | Why? |
| Weight Gain | 6 | 2019 | 552 | 0.37 | Why? |
| Patient Acceptance of Health Care | 2 | 2017 | 5002 | 0.35 | Why? |
| Drug Therapy, Combination | 3 | 2017 | 7268 | 0.33 | Why? |
| Glucagon-Like Peptide-1 Receptor | 2 | 2018 | 138 | 0.32 | Why? |
| Patient Care Management | 1 | 2018 | 1514 | 0.32 | Why? |
| Humans | 86 | 2021 | 930598 | 0.31 | Why? |
| Adolescent | 31 | 2021 | 86841 | 0.31 | Why? |
| Substance-Related Disorders | 2 | 2018 | 2038 | 0.30 | Why? |
| Symptom Assessment | 1 | 2019 | 4967 | 0.28 | Why? |
| Quality of Life | 5 | 2021 | 9820 | 0.27 | Why? |
| Diabetes Mellitus, Type 2 | 4 | 2018 | 6166 | 0.26 | Why? |
| Regression Analysis | 4 | 2019 | 2484 | 0.25 | Why? |
| Injections | 3 | 2019 | 237 | 0.25 | Why? |
| Health Services Accessibility | 2 | 2017 | 10697 | 0.25 | Why? |
| Bulimia Nervosa | 2 | 2017 | 25 | 0.22 | Why? |
| Body Mass Index | 6 | 2019 | 4306 | 0.22 | Why? |
| Psychopharmacology | 1 | 2019 | 18 | 0.21 | Why? |
| Holistic Health | 1 | 2021 | 90 | 0.20 | Why? |
| Central Nervous System Stimulants | 2 | 2018 | 111 | 0.20 | Why? |
| Risperidone | 1 | 2019 | 55 | 0.20 | Why? |
| Affective Disorders, Psychotic | 1 | 2018 | 13 | 0.20 | Why? |
| Drug Monitoring | 2 | 2018 | 1408 | 0.19 | Why? |
| Algorithms | 1 | 2017 | 7346 | 0.19 | Why? |
| Venlafaxine Hydrochloride | 1 | 2018 | 30 | 0.19 | Why? |
| Anorexia Nervosa | 2 | 2017 | 103 | 0.19 | Why? |
| Abnormal Involuntary Movement Scale | 1 | 2018 | 1 | 0.19 | Why? |
| Male | 41 | 2019 | 367725 | 0.19 | Why? |
| Dopamine Antagonists | 1 | 2018 | 13 | 0.19 | Why? |
| Administration, Cutaneous | 1 | 2019 | 229 | 0.18 | Why? |
| Mass Screening | 1 | 2019 | 8005 | 0.18 | Why? |
| Social Conditions | 1 | 2021 | 196 | 0.18 | Why? |
| Age of Onset | 2 | 2017 | 557 | 0.18 | Why? |
| D-Amino-Acid Oxidase | 1 | 2017 | 2 | 0.18 | Why? |
| Neuregulin-1 | 1 | 2017 | 8 | 0.18 | Why? |
| Female | 42 | 2019 | 380317 | 0.18 | Why? |
| Catechol O-Methyltransferase | 1 | 2017 | 25 | 0.18 | Why? |
| Least-Squares Analysis | 1 | 2018 | 254 | 0.18 | Why? |
| Nutritional Physiological Phenomena | 1 | 2019 | 100 | 0.18 | Why? |
| Body Weight | 3 | 2018 | 1074 | 0.18 | Why? |
| Physicians | 1 | 2017 | 4214 | 0.17 | Why? |
| Borderline Personality Disorder | 1 | 2017 | 44 | 0.17 | Why? |
| Depressive Disorder | 2 | 2019 | 1236 | 0.17 | Why? |
| Naltrexone | 1 | 2017 | 56 | 0.17 | Why? |
| Reproducibility of Results | 7 | 2018 | 11304 | 0.17 | Why? |
| Early Diagnosis | 2 | 2017 | 2443 | 0.17 | Why? |
| Obesity | 5 | 2018 | 7388 | 0.17 | Why? |
| Neutropenia | 2 | 2020 | 388 | 0.17 | Why? |
| Neuromuscular Agents | 1 | 2017 | 87 | 0.17 | Why? |
| Pain Perception | 1 | 2017 | 48 | 0.17 | Why? |
| Medication Therapy Management | 2 | 2017 | 312 | 0.16 | Why? |
| Polymorphism, Genetic | 2 | 2017 | 1074 | 0.16 | Why? |
| Overweight | 3 | 2018 | 916 | 0.16 | Why? |
| Hyperalgesia | 1 | 2017 | 61 | 0.16 | Why? |
| Injections, Intramuscular | 1 | 2019 | 800 | 0.16 | Why? |
| Social Adjustment | 1 | 2017 | 77 | 0.16 | Why? |
| Cholesterol, LDL | 2 | 2017 | 499 | 0.16 | Why? |
| Hypoglycemic Agents | 3 | 2018 | 2165 | 0.16 | Why? |
| Dopamine | 1 | 2017 | 123 | 0.16 | Why? |
| Osteoarthritis | 1 | 2019 | 205 | 0.16 | Why? |
| Aggression | 1 | 2017 | 126 | 0.16 | Why? |
| Leptin | 1 | 2017 | 141 | 0.16 | Why? |
| Prescriptions | 1 | 2017 | 258 | 0.15 | Why? |
| Adult | 26 | 2019 | 244371 | 0.15 | Why? |
| Hospitalization | 5 | 2019 | 54280 | 0.15 | Why? |
| Drug Administration Schedule | 2 | 2019 | 2324 | 0.15 | Why? |
| Child | 13 | 2021 | 70012 | 0.15 | Why? |
| Prediabetic State | 1 | 2017 | 200 | 0.14 | Why? |
| Anti-Bacterial Agents | 1 | 2017 | 10083 | 0.14 | Why? |
| Drug Utilization | 2 | 2017 | 619 | 0.14 | Why? |
| Young Adult | 18 | 2019 | 93724 | 0.14 | Why? |
| Polymorphism, Single Nucleotide | 2 | 2018 | 3607 | 0.14 | Why? |
| Polypharmacy | 1 | 2017 | 347 | 0.14 | Why? |
| Secondary Prevention | 1 | 2019 | 762 | 0.14 | Why? |
| Statistics as Topic | 1 | 2017 | 370 | 0.13 | Why? |
| Emergency Services, Psychiatric | 1 | 2017 | 175 | 0.13 | Why? |
| Carrier Proteins | 1 | 2017 | 513 | 0.13 | Why? |
| Treatment Outcome | 10 | 2019 | 51732 | 0.13 | Why? |
| Remission Induction | 1 | 2017 | 950 | 0.13 | Why? |
| Middle Aged | 21 | 2019 | 270681 | 0.13 | Why? |
| Parent-Child Relations | 1 | 2017 | 384 | 0.13 | Why? |
| Metabolome | 1 | 2018 | 624 | 0.13 | Why? |
| Narcotic Antagonists | 1 | 2017 | 317 | 0.13 | Why? |
| Follow-Up Studies | 5 | 2018 | 17020 | 0.12 | Why? |
| Metabolic Diseases | 1 | 2018 | 505 | 0.12 | Why? |
| Drug Interactions | 1 | 2020 | 1653 | 0.12 | Why? |
| Drug Prescriptions | 2 | 2018 | 1062 | 0.12 | Why? |
| Combined Modality Therapy | 2 | 2018 | 3395 | 0.12 | Why? |
| Off-Label Use | 1 | 2017 | 553 | 0.12 | Why? |
| Treatment Failure | 1 | 2018 | 2106 | 0.12 | Why? |
| Decision Support Systems, Clinical | 1 | 2017 | 551 | 0.12 | Why? |
| Receptors, Neurotransmitter | 1 | 2010 | 10 | 0.11 | Why? |
| Metformin | 1 | 2018 | 640 | 0.11 | Why? |
| Time Factors | 4 | 2019 | 31397 | 0.11 | Why? |
| Feeding and Eating Disorders | 1 | 2017 | 525 | 0.11 | Why? |
| Coronavirus | 1 | 2020 | 18339 | 0.11 | Why? |
| Informed Consent | 1 | 2018 | 890 | 0.11 | Why? |
| Sex Characteristics | 1 | 2018 | 1120 | 0.10 | Why? |
| Autism Spectrum Disorder | 1 | 2018 | 587 | 0.10 | Why? |
| Denmark | 4 | 2019 | 2654 | 0.10 | Why? |
| Metabolic Syndrome | 1 | 2018 | 810 | 0.10 | Why? |
| Self Report | 2 | 2019 | 3802 | 0.10 | Why? |
| Congresses as Topic | 1 | 2019 | 1347 | 0.10 | Why? |
| Mental Health | 3 | 2021 | 15770 | 0.10 | Why? |
| Dose-Response Relationship, Drug | 1 | 2018 | 3776 | 0.10 | Why? |
| Cardiovascular Diseases | 3 | 2018 | 11497 | 0.09 | Why? |
| Emotions | 1 | 2021 | 2418 | 0.09 | Why? |
| Heart Rate | 1 | 2017 | 1527 | 0.09 | Why? |
| Piperazines | 1 | 2011 | 445 | 0.09 | Why? |
| Pre-Exposure Prophylaxis | 1 | 2017 | 1138 | 0.09 | Why? |
| Risk Factors | 7 | 2018 | 71621 | 0.09 | Why? |
| Longitudinal Studies | 3 | 2021 | 9893 | 0.09 | Why? |
| Cross-Sectional Studies | 4 | 2019 | 53120 | 0.08 | Why? |
| Waist Circumference | 2 | 2017 | 199 | 0.08 | Why? |
| Consensus | 2 | 2020 | 6345 | 0.08 | Why? |
| Employment | 1 | 2018 | 1754 | 0.08 | Why? |
| Thiazoles | 1 | 2011 | 496 | 0.08 | Why? |
| Diagnosis, Differential | 2 | 2018 | 7220 | 0.08 | Why? |
| Health Promotion | 1 | 2019 | 2020 | 0.08 | Why? |
| Research | 1 | 2018 | 2115 | 0.07 | Why? |
| Health Status | 1 | 2019 | 3259 | 0.07 | Why? |
| Patient Selection | 1 | 2019 | 4560 | 0.07 | Why? |
| Delivery of Health Care, Integrated | 1 | 2016 | 1549 | 0.07 | Why? |
| United States | 5 | 2018 | 46150 | 0.07 | Why? |
| Parkinson Disease | 1 | 2017 | 1414 | 0.07 | Why? |
| Cohort Studies | 5 | 2019 | 36005 | 0.07 | Why? |
| Community Mental Health Services | 2 | 2017 | 217 | 0.07 | Why? |
| Pneumonia, Viral | 6 | 2020 | 243684 | 0.06 | Why? |
| Coronavirus Infections | 6 | 2020 | 253789 | 0.06 | Why? |
| Mental Health Services | 1 | 2020 | 3007 | 0.06 | Why? |
| Pandemics | 8 | 2021 | 389249 | 0.06 | Why? |
| Risk | 3 | 2020 | 5288 | 0.06 | Why? |
| Disease Management | 1 | 2020 | 6841 | 0.06 | Why? |
| Insulin Resistance | 2 | 2017 | 669 | 0.06 | Why? |
| Prospective Studies | 4 | 2019 | 43301 | 0.06 | Why? |
| Brain | 1 | 2017 | 5133 | 0.05 | Why? |
| Desvenlafaxine Succinate | 1 | 2018 | 3 | 0.05 | Why? |
| Severity of Illness Index | 2 | 2018 | 48226 | 0.05 | Why? |
| Practice Patterns, Physicians' | 1 | 2018 | 4927 | 0.05 | Why? |
| Blood Glucose | 3 | 2017 | 3642 | 0.04 | Why? |
| Mental Health Recovery | 1 | 2017 | 24 | 0.04 | Why? |
| Episode of Care | 1 | 2017 | 27 | 0.04 | Why? |
| Intelligence | 1 | 2018 | 89 | 0.04 | Why? |
| Disease Progression | 1 | 2017 | 13580 | 0.04 | Why? |
| Actigraphy | 1 | 2017 | 102 | 0.04 | Why? |
| Connectome | 1 | 2017 | 67 | 0.04 | Why? |
| Exercise | 1 | 2017 | 6771 | 0.04 | Why? |
| Rest | 1 | 2017 | 188 | 0.04 | Why? |
| Sensitivity and Specificity | 1 | 2018 | 22971 | 0.04 | Why? |
| Fitness Trackers | 1 | 2017 | 120 | 0.04 | Why? |
| Neural Pathways | 1 | 2017 | 155 | 0.04 | Why? |
| Finland | 1 | 2019 | 671 | 0.04 | Why? |
| Prognosis | 2 | 2017 | 32490 | 0.04 | Why? |
| Translations | 1 | 2017 | 153 | 0.04 | Why? |
| Child Psychiatry | 1 | 2018 | 107 | 0.04 | Why? |
| Observer Variation | 1 | 2018 | 622 | 0.04 | Why? |
| Electric Impedance | 1 | 2017 | 283 | 0.04 | Why? |
| Intracellular Signaling Peptides and Proteins | 1 | 2017 | 334 | 0.04 | Why? |
| Betacoronavirus | 6 | 2020 | 204454 | 0.04 | Why? |
| International Classification of Diseases | 1 | 2017 | 265 | 0.04 | Why? |
| Triglycerides | 1 | 2017 | 478 | 0.03 | Why? |
| Adiposity | 1 | 2017 | 329 | 0.03 | Why? |
| Cholesterol, HDL | 1 | 2017 | 439 | 0.03 | Why? |
| Genetic Association Studies | 1 | 2017 | 559 | 0.03 | Why? |
| North America | 1 | 2019 | 1400 | 0.03 | Why? |
| Aged | 7 | 2018 | 215776 | 0.03 | Why? |
| Quality-Adjusted Life Years | 1 | 2016 | 511 | 0.03 | Why? |
| Cholesterol | 1 | 2017 | 660 | 0.03 | Why? |
| Pharmacovigilance | 1 | 2017 | 501 | 0.03 | Why? |
| Gene Frequency | 1 | 2017 | 1210 | 0.03 | Why? |
| Self-Injurious Behavior | 1 | 2017 | 391 | 0.03 | Why? |
| Adverse Drug Reaction Reporting Systems | 1 | 2017 | 694 | 0.03 | Why? |
| Medicaid | 1 | 2017 | 492 | 0.03 | Why? |
| Anticonvulsants | 1 | 2017 | 634 | 0.03 | Why? |
| Demography | 1 | 2019 | 1660 | 0.03 | Why? |
| Healthy Volunteers | 1 | 2017 | 1444 | 0.03 | Why? |
| Practice Guidelines as Topic | 4 | 2018 | 15421 | 0.03 | Why? |
| Language | 1 | 2017 | 655 | 0.03 | Why? |
| Linear Models | 1 | 2017 | 1914 | 0.03 | Why? |
| Sweden | 1 | 2018 | 1969 | 0.03 | Why? |
| Alcoholism | 1 | 2018 | 691 | 0.03 | Why? |
| Sex Distribution | 1 | 2018 | 2083 | 0.03 | Why? |
| United States Food and Drug Administration | 1 | 2017 | 1276 | 0.02 | Why? |
| Cluster Analysis | 1 | 2018 | 3001 | 0.02 | Why? |
| Biological Specimen Banks | 1 | 2017 | 1142 | 0.02 | Why? |
| Kaplan-Meier Estimate | 1 | 2019 | 4260 | 0.02 | Why? |
| Glycated Hemoglobin A | 1 | 2017 | 1316 | 0.02 | Why? |
| Telemedicine | 1 | 2020 | 25032 | 0.02 | Why? |
| Case-Control Studies | 2 | 2017 | 17671 | 0.02 | Why? |
| Insulin | 1 | 2017 | 1316 | 0.02 | Why? |
| Lipids | 1 | 2015 | 1079 | 0.02 | Why? |
| Age Distribution | 1 | 2018 | 3567 | 0.02 | Why? |
| Leukocyte Count | 1 | 2017 | 3178 | 0.02 | Why? |
| Internationality | 1 | 2020 | 3297 | 0.02 | Why? |
| Evidence-Based Medicine | 1 | 2020 | 3228 | 0.02 | Why? |
| Proportional Hazards Models | 1 | 2019 | 6543 | 0.02 | Why? |
| Cost-Benefit Analysis | 1 | 2016 | 2259 | 0.02 | Why? |
| Multivariate Analysis | 1 | 2017 | 5440 | 0.02 | Why? |
| Molecular Structure | 1 | 2011 | 1539 | 0.02 | Why? |
| Blood Pressure | 1 | 2017 | 2198 | 0.02 | Why? |
| Odds Ratio | 1 | 2017 | 5861 | 0.02 | Why? |
| Genotype | 1 | 2017 | 4697 | 0.02 | Why? |
| Psychiatry | 1 | 2018 | 1289 | 0.02 | Why? |
| Quality Improvement | 1 | 2017 | 2435 | 0.02 | Why? |
| Quality of Health Care | 1 | 2016 | 1948 | 0.02 | Why? |
| Guideline Adherence | 1 | 2017 | 2309 | 0.02 | Why? |
| Databases, Factual | 1 | 2019 | 6248 | 0.02 | Why? |
| Patient Satisfaction | 1 | 2016 | 2517 | 0.02 | Why? |
| Electrocardiography | 1 | 2017 | 3957 | 0.02 | Why? |
| Child, Preschool | 2 | 2018 | 36283 | 0.02 | Why? |
| Depression | 2 | 2018 | 14116 | 0.02 | Why? |
| Risk Assessment | 2 | 2017 | 25439 | 0.02 | Why? |
| Europe | 1 | 2019 | 12702 | 0.02 | Why? |
| Adaptation, Psychological | 1 | 2021 | 4996 | 0.02 | Why? |
| Surveys and Questionnaires | 2 | 2021 | 43792 | 0.01 | Why? |
| Sex Factors | 1 | 2019 | 11014 | 0.01 | Why? |
| Socioeconomic Factors | 1 | 2019 | 8495 | 0.01 | Why? |
| Animals | 1 | 2010 | 78931 | 0.01 | Why? |
| Machine Learning | 1 | 2017 | 4395 | 0.01 | Why? |
| Magnetic Resonance Imaging | 1 | 2017 | 6551 | 0.01 | Why? |
| Logistic Models | 1 | 2015 | 9089 | 0.01 | Why? |
| Acute Disease | 1 | 2011 | 6029 | 0.01 | Why? |
| Registries | 1 | 2018 | 12327 | 0.01 | Why? |
| Age Factors | 1 | 2019 | 21039 | 0.01 | Why? |
| Biomedical Research | 1 | 2018 | 5270 | 0.01 | Why? |
| Retrospective Studies | 2 | 2018 | 105322 | 0.01 | Why? |
| Public Health | 1 | 2020 | 16359 | 0.01 | Why? |
| Comorbidity | 1 | 2019 | 34796 | 0.01 | Why? |
| Biomarkers | 1 | 2017 | 23361 | 0.01 | Why? |
| Clinical Laboratory Techniques | 1 | 2020 | 23402 | 0.01 | Why? |
| Italy | 1 | 2017 | 38444 | 0.01 | Why? |
| Anxiety | 1 | 2018 | 17311 | 0.01 | Why? |
| Health Personnel | 1 | 2020 | 29646 | 0.01 | Why? |
| Aged, 80 and over | 1 | 2018 | 88759 | 0.01 | Why? |